Author  
Place of duty  
Title   전이성 유방암에 대한 Paclitaxel 제 2 상 다기관 공동 임상시험 ( Phase II Multicenter Trial of Paclitaxel for Metastatic Breast Cancer )
Publicationinfo   2000 Jan; 032(03): 545-553.
Key_word   Breast neoplasm , Chemotherapy , Paclitaxel , Phase II
Full-Text  
Abstract   Purpose: To evaluate the efficacy and safety of paclitaxel for metastatic breast cancer patients who had received previous chemotherapy, we have performed phase II multiconter trial between December 1997 and December 1998. Materials and Method: Thirty patients were accrued to this study and paclitaxel was administered at 175 mg/m as a 3-hour intravenous infusion every 3 weeks until the progression of the disease. Results: Objective respanse were observed in 13 of 30 patients (43.3%), There were 1 complete response (3.3%) and 12 partial responses (40%). Especially, 50% (11/22) of patients who had received prior anthracycline-containing regimens for adjuvant or metastatic disease responded to paclitaxel. Responses were observed in all sites of metastatic disease. One hundred forty-nine cycles of treatment were administered, with a median of six cycles per patient. Grade III and IV toxicities included neutropenia (24%), elevated liver enzyme (10%), peripheral neuropathy (10%), arthralgia/myalgia (23%), and alopecia (87%). No significant hypersensitivity type reaction or cardiac arrhythmia were seen. Median duration of response was 7.2 months. Conclusions: These results suggested that paclitaxel is active therapeutic agent in metastatic breast cancer patients and it can be safely administered by 3-hour intravenous infusion with premedication.
저 자   김성록(Sung Rok Kim),변재호(Jae Ho Byun),윤성수(Sung Soo Yoon),박찬형(Chan Hyung Park),김시영(Si Young Kim),김효진(Hyo Jin Kim),방수미(Soo Mee Bang),장흥문(Heung Moon Chang),허대석(Dae Seog Heo),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim)